Steven Tong

Want to come work on SNAP, BALANCE+, and STRAP? And change how we treat and manage bloodstream infections? See below. #IDSky

Great to speak with @thelancetinfdis.bsky.social together with @gurujosh.bsky.social about adaptive platform trials in infectious diseases!

We’re kicking off #Antimicrobials2026 with Symposium 1: Staphylococcus aureus, featuring two outstanding speakers.

💊 Prof @steventong.bsky.social
SNAP Update

🧬 Prof Anton Y. Peleg
Daptomycin and MRSA

Register now: www.antimicrobials.com.au
#MRSA #idsky #amssky #clinmicrosky

🆕🔥🔥CloCeBa RCT
Cloxacillin versus cefazolin for MSSA Bacteraemia
Cefazolin has a non-inferior efficacy regarding mortality, microbiological or clinical endpoints and was associated with a lower rate of serious adverse events #IDSky
www.thelancet.com/journals/lan...

Nice piece Ilan. Certainly nostalgic for the old Twitter. Unfortuantely the discussion / engagement on BlueSky for #IDSky hasn't been as good. It does actually need more people with stronger opinions to make it more fun I think

International funding flows in infectious diseases clinical trials published in selected high-impact journals over a 10-year period

New paper in @cmijournal.bsky.social, led by @seanong.bsky.social.

See thread for details.

@thedohertyinst.bsky.social @unimelb.bsky.social #IDSky

Congratulations Amy!! Well deserved. It’s been such a pleasure to see you achieve this body of work

Not as yet. Considering it

Free access to our article on the inclusion of LMICs in platform trials of bloodstream infections. SNAP in Johannesburg. @steventong.bsky.social @gurujosh.bsky.social

authors.elsevier.com/a/1lVzy,RGPg...

Glad to have the opportunity to collaborate with Spanish colleagues on this. We conducted a pooled Bayesian post-hoc analysis of the BACSARM and SAFO trials evaluating combination therapy with fosfomycin for SAB. The door may not be closed on adjunctive fosfomycin! Justifies need for more RCTs.

The Staphylococcus aureus Network Adaptive Platform (SNAP) trial has been nominated for a Patient healthcare communication award!

Public voting is now open 👉 ccrew.accesscr.com.au/cpir-2025/pu...

Find out more about SNAP 🔗 www.snaptrial.com.au

Give us a vote!!

@thedohertyinst.bsky.social

Thrilled to share our new research led by Jane Davies @menziesresearch.bsky.social on First Nations people in the NT living with chronic hepatitis B. An important study that could inform better care:

doi.org/10.1186/s128...

#idsky #MedSky #HepSky #LiverSky

Trials Within Trials—Optimizing the Delivery of RCTs In the latest issue of JAMA, Johansen and colleagues1 report the results of a trial that investigated the impact of digital recruitment letter formats on recruitment to a larger clinical trial, the DA...

Thankful for another opportunity to write this editorial with @steventong.bsky.social in @jama.com: jamanetwork.com/journals/jam...

We discuss this trial, which evaluated the impact of different recruitment letter formats on RCT enrolment: jamanetwork.com/journals/jam...

Tuberculosis (TB), an infectious disease caused by bacteria, was responsible for as many as one-quarter of all deaths in the US and Europe during parts of the 18th and 19th centuries.

However, as we see in the chart for England and Wales, deaths from TB have declined dramatically in rich countries.

I was worried the results were going to be applied to Staph aureus! Got to watch to the end

Making sense of hierarchical composite endpoints in randomized clinical trials – a primer for infectious disease clinicians and researchers Hierarchical composite endpoints (HCEs) are increasingly being used in infectious diseases research. In this review aimed at educating the clinical reader,

Our review on hierarchical composite endpoints (HCEs) has just been published in @cidjournal.bsky.social:
doi.org/10.1093/cid/...

We provide a conceptual overview of HCEs, explain the different associated target parameters and analytic methods.

@steventong.bsky.social @gurujosh.bsky.social

I learnt so much from @seanong.bsky.social in reading / drafting this multiple times! Hope it will be a useful piece for everyone

Thanks for posting all these Stuart!!

Dr K Gibney flys the flag for 🦘 clin trials by 🎺

ISAAC 🔎 at Abx prophylaxis of close iGAS contacts (enrolling soon)

STRAP 🔎 backbone Abx, adjunctive Abx, and IVIg (enrolling 2026ish)

Only enrolling in Aus for now but looking for int. collab.

#LISSSD25 #idsky #clinicaltrials #strep

Kick off the new season with our latest issue. 😄

Donate to level-up mental health in Australia Help raise funds for much-needed mental health services and initiatives by donating to my page. I’m completing The Push-Up Challenge to support this great cause and would love your help to reach my fu...

Have joined a Push-Up challenge to raise awareness and funds for mental health. 3,214 push-ups in 23 days.
www.thepushupchallenge.com.au/fundraiser/s...

PROMOAT: What is the optimal antibiotic regimen for women with premature, prelabour rupture of membranes (PPROM)?

BabyCINO: Comparing the different doses and regimens of caffeine given to very preterm infants with apnoea of prematurity (breathing problems)

Exciting to see this new adaptive platform trial!

For pregnant women and people who are at risk of preterm birth, and babies born preterm.

PLATIPUS (Platform for Adaptive Trial in Perinatal UnitS)

@platipus.bsky.social @drbretty.bsky.social

First domains will be: PROMOAT and BabyCINO

Always a privilege to write with @seanong.bsky.social!

We will see in SNAP. We randomise to PET or not and then leave it up to treating clinicians as to what they do with the result

Forest plot of 30 day all cause mortality which favors cefazolin (OR=0.73, 95%CI=0.62-0.85)

Forest plot of discontinuation due to adverse effects which favors cefazolin (OR=0.13, 95%CI=0.06-0.27)

Cefazolin vs Antistaphylococcal Penicillins for Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Systematic Review & Meta-Analysis

@connorprosty.bsky.social @seanong.bsky.social &c

Cefaz more effective, safer #idsky
www.clinicalmicrobiologyandinfection.com/article/S119... 🔓

Cefazolin versus Antistaphylococcal Penicillins for the Treatment of Methicillin-Susceptible Staphylococcus aureus Bacteremia: A Systematic Review and Meta-Analysis There is debate on whether cefazolin or antistaphylococcal penicillins should be the first-line treatment for methicillin-susceptible Staphylococcus aureus (MSSA) bacteremia. Ongoing trials are invest...

🆕💫 Systematic Review and Meta-Analysis
30 observational studies( SNAP & CloCeBa not included)
N: 3869
Cefazolin versus Antistaphylococcal Penicillins for the Treatment of MSSA Bacteremia #idsky
www.clinicalmicrobiologyandinfection.com/article/S119...

Our new paper in @cmijournal.bsky.social, a systematic review where we evaluated reporting of baseline sociodemographic characteristics across 1343 ID clinical trials over a 10-year period. A 🧵:

@steventong.bsky.social #IDSky

doi.org/10.1016/j.cm...

SNAP Out of It: Rethinking Antistaphylococcal Penicillins for S. Aureus Bacteremia – The SNAP Trial PSSA/MSSA Results Podcast Episode · Breakpoints · 05/04/2025 · 1h 11m

such a joy to discuss PSSA/MSSA domains of SNAP. incredible work led by @gurujosh.bsky.social @steventong.bsky.social conversation w/ the fabulous @angelahuttner.bsky.social

joint effort @escmid.bsky.social Communicable & @sidpharm.bsky.social Breakpoints podcast

podcasts.apple.com/us/podcast/s...

🆕 Episode of #Breakpoints/Communicable:
Breakpoints joins forces w @cmicomms.bsky.social podcast to discuss the highly anticipated SNAP trial updates presented at ESCMID Global 2025.

Listen to Breakpoints: sidp.pinecast.co | breakpoints-sidp.org
Listen to Communicable: communicable.transistor.fm